Skip to Content
You are currently on the new version of our website. Access the old version .

317 Results Found

  • Review
  • Open Access
22 Citations
6,201 Views
13 Pages

Recent Advances in Optically Controlled PROTAC

  • Muzi Ouyang,
  • Ying Feng,
  • Hui Chen,
  • Yanping Liu and ,
  • Chunyan Tan and
  • Ying Tan
  • + 1 author+ 0 author

Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivi...

(This article belongs to the Section Biochemical Engineering)
  • Review
  • Open Access
14 Citations
4,936 Views
19 Pages

Recent Advances in the Development of Pro-PROTAC for Selective Protein Degradation

  • Fady Hakem,
  • Ahmad Abdelwaly,
  • Reem Alshaman,
  • Abdullah Alattar and ,
  • Fawaz E. Alanazi,
  • Sawsan A. Zaitone and
  • Mohamed A. Helal
  • + 2 authors+ 0 author

PROTACs are trimeric small molecules consisting of a specific modulator of the target protein connected to a ligase-recruiting ligand via a suitably flexible linker. Ligase-recruiting ligands deliver ubiquitin ligases like E3 ligase to the Protein of...

(This article belongs to the Section Drug Targeting and Design)
  • Review
  • Open Access
13 Citations
6,278 Views
40 Pages

An Update on Clinically Advanced PROTAC Degraders and Their Synthesis

  • Ranjan Kumar Acharyya,
  • Yugandhar Kothapalli,
  • Suresh Yarlagadda,
  • Chayan K. De and ,
  • Srinivasa Rao Allu,
  • Joyeeta Roy and
  • Rohan Kalyan Rej
  • + 2 authors+ 0 author

22 December 2025

Proteolysis-targeting chimeras (PROTACs) have emerged as a revolutionary therapeutic modality that enables degradation of therapeutically relevant proteins through the protein disposal machinery, the ubiquitin-proteasome system (UPS). Unlike traditio...

(This article belongs to the Section Medicinal Chemistry)
  • Review
  • Open Access
27 Citations
11,633 Views
31 Pages

PROTAC Technology as a New Tool for Modern Pharmacotherapy

  • Natalia Kubryń,
  • Łukasz Fijałkowski,
  • Jacek Nowaczyk,
  • Amer Jamil and
  • Alicja Nowaczyk

The publication focuses on the innovative applications of PROTAC (proteolysis-targeting chimera) technology in modern pharmacotherapy, with particular emphasis on cancer treatment. PROTACs represent an advanced therapeutic strategy that enables selec...

  • Review
  • Open Access
62 Citations
14,747 Views
21 Pages

Drug development for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease has challenging difficulties due to the pharmacokinetic impermeability based on the blood-brain barrier (BBB)...

(This article belongs to the Special Issue Antibodies: 10th Anniversary)
  • Review
  • Open Access
27 Citations
15,546 Views
17 Pages

11 January 2024

PROTAC is a rapidly developing engineering technology for targeted protein degradation using the ubiquitin–proteasome system, which has promising applications for inflammatory diseases, neurodegenerative diseases, and malignant tumors. This pap...

(This article belongs to the Section Pharmacology)
  • Review
  • Open Access
19 Citations
4,989 Views
22 Pages

25 November 2025

Proteolysis Targeting Chimeras (PROTACs) represent a transformative modality in drug discovery, enabling the selective degradation of disease-relevant proteins through the ubiquitin proteasome system. Despite their therapeutic promise, the rational d...

(This article belongs to the Special Issue Computer-Aided Drug Design and Drug Discovery, 2nd Edition)
  • Review
  • Open Access
1 Citations
875 Views
22 Pages

PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives

  • Pasquale Degennaro,
  • Imane Ghafir El Idrissi,
  • Rosa Purgatorio,
  • Annalisa Fanizzi and ,
  • Mariagrazia Rullo,
  • Leonardo Pisani,
  • Eleonora Macchia,
  • Luisa Torsi,
  • Angela Stefanachi and
  • Francesco Leonetti
  • + 5 authors+ 0 author

26 August 2026

Proteolysis-Targeting Chimeras (PROTACs) are heterobifunctional molecules that induce the selective degradation of a protein of interest by recruiting an E3 ubiquitin ligase, thereby triggering ubiquitination and proteasomal clearance. As part of the...

(This article belongs to the Topic Imatinib (Glivec or Gleevec): Commemorative Topic in Honor of Dr. Jürg Zimmermann)
  • Article
  • Open Access
10 Citations
5,786 Views
17 Pages

Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α

  • Mónica Cubillos-Rojas,
  • Guillem Loren,
  • Yusuf Z. Hakim,
  • Xavier Verdaguer and ,
  • Antoni Riera and
  • Angel R. Nebreda
  • + 1 author+ 0 author

18 January 2023

We report a series of small molecule proteolysis-targeting chimeras (PROTACs) that target the protein kinase p38α for degradation. These PROTACs are based on a ligand of the VHL E3 ubiquitin ligase, which is linked to an ATP competitive inhibit...

(This article belongs to the Special Issue Targeting Mechanisms of Protein Degradation for Cancer Therapy)
  • Review
  • Open Access
7 Citations
10,826 Views
28 Pages

The Expanding E3 Ligase-Ligand Landscape for PROTAC Technology

  • Zhenzhen Li,
  • Xiaoli Huang,
  • Xuchi Zhao,
  • Yunxiu Zhang and
  • Ping Li

27 September 2025

Proteolysis-targeting chimeras (PROTACs) are a transformative therapeutic modality that co-opts the ubiquitin-proteasome system for selective protein degradation. To date, the development of PROTACs has been overwhelmingly dominated by the recruitmen...

(This article belongs to the Special Issue Comprehending Molecular Targets: Mechanisms and Actions in Drug Development)
  • Review
  • Open Access
49 Citations
8,772 Views
20 Pages

Recent Advances in PROTAC-Based Antiviral Strategies

  • Haleema Ahmad,
  • Bushra Zia,
  • Hashir Husain and
  • Afzal Husain

27 January 2023

Numerous mysteries of cell and molecular biology have been resolved through extensive research into intracellular processes, which has also resulted in the development of innovative technologies for the treatment of infectious and non-infectious dise...

  • Review
  • Open Access
37 Citations
8,859 Views
18 Pages

3 June 2025

Transcription factors (TFs) play central roles in gene regulation and disease progression but have long been considered undruggable due to the absence of well-defined binding pockets and their reliance on protein–protein or protein–DNA in...

(This article belongs to the Section Cancer Drug Development)
  • Article
  • Open Access
1 Citations
1,674 Views
23 Pages

PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells

  • Yeongji Kim,
  • Jin-Woo Kim,
  • Junwon Choi,
  • Jinhyeong Kim and ,
  • Soyeon Park,
  • Wonji Choi,
  • Hyunju An,
  • Jinman Kim,
  • Minsup Kim and
  • Soonchul Lee
  • + 8 authors+ 3 authors

5 March 2026

Osteosarcoma, the most common malignant bone tumor in young individuals, often exhibits poor outcomes due to MDM2-mediated suppression of the p53 pathway. Whereas conventional MDM2 inhibitors block the p53–MDM2 interaction but frequently induce...

  • Review
  • Open Access
5 Citations
3,673 Views
17 Pages

PROTAC-Based Antivirals for Respiratory Viruses: A Novel Approach for Targeted Therapy and Vaccine Development

  • Amith Anugu,
  • Pankaj Singh,
  • Dharambir Kashyap,
  • Jillwin Joseph and ,
  • Sheetal Naik,
  • Subhabrata Sarkar,
  • Kamran Zaman,
  • Manpreet Dhaliwal,
  • Shubham Nagar and
  • Prasanna Honnavar
  • + 6 authors+ 1 author

The global burden of respiratory viral infections is notable, which is attributed to their higher transmissibility compared to other viral diseases. Respiratory viruses are seen to have evolved resistance to available treatment options. Although vacc...

(This article belongs to the Section Virology)
  • Review
  • Open Access
81 Citations
12,241 Views
31 Pages

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation

  • Endry Wahyu Syahputra,
  • Hyunji Lee,
  • Hyukjun Cho,
  • Hyun Jin Park and ,
  • Kwang-Su Park and
  • Duhyeong Hwang
  • + 1 author+ 0 author

Proteolysis targeting chimeras (PROTACs), heterobifunctional molecules that hijack the ubiquitin–proteasome system (UPS) to degrade specific proteins, hold great promise in treating diseases driven by traditionally “undruggable” tar...

(This article belongs to the Special Issue Drug Nanocarriers for Pharmaceutical Applications)
  • Article
  • Open Access
1 Citations
1,448 Views
30 Pages

PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells

  • Nikola Knoll,
  • Kayra Somay,
  • Purushottam B. Tiwari,
  • Emre Deniz and ,
  • Jeffrey S. S. K. Formen,
  • Isabel Frye,
  • Eryn Nelson,
  • Christian Wolf,
  • Jeffrey A. Toretsky and
  • Aykut Üren
  • + 5 authors+ 0 author

23 July 2026

Background/Objectives: Fusion-positive rhabdomyosarcoma (FP-RMS) is characterized by the presence of tumor-specific chromosomal translocation products, most commonly PAX3::FOXO1, and typically results in lower survival rates compared to fusion-negati...

(This article belongs to the Section Pediatric Oncology)
  • Review
  • Open Access
45 Citations
8,585 Views
18 Pages

Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development

  • Danishuddin,
  • Mohammad Sarwar Jamal,
  • Kyoung-Seob Song,
  • Keun-Woo Lee and ,
  • Jong-Joo Kim and
  • Yeong-Min Park
  • + 1 author+ 0 author

24 November 2023

PROteolysis TArgeting Chimera (PROTAC) is an emerging technology in chemical biology and drug discovery. This technique facilitates the complete removal of the target proteins that are “undruggable” or challenging to target through chemic...

(This article belongs to the Section Medicinal Chemistry)
  • Review
  • Open Access
39 Citations
5,920 Views
30 Pages

Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy

  • Xiaoqing Wu,
  • Yueli Shu,
  • Yao Zheng,
  • Peichuan Zhang and ,
  • Hanwen Cong,
  • Yingpei Zou,
  • Hao Cai and
  • Zhengyu Zha
  • + 3 authors+ 0 author

Proteolysis-targeting chimeras (PROTACs) selectively degrade target proteins by recruiting intracellular E3 ubiquitin ligases, overcoming the limitations of traditional small-molecule inhibitors that merely block protein function. This approach has g...

(This article belongs to the Special Issue Prodrug Strategies for Enhancing Drug Stability and Pharmacokinetics)
  • Review
  • Open Access
28 Citations
13,029 Views
26 Pages

15 November 2023

Sarcomas are heterogeneous bone and soft tissue cancers representing the second most common tumor type in children and adolescents. Histology and genetic profiling discovered more than 100 subtypes, which are characterized by peculiar molecular vulne...

(This article belongs to the Special Issue Sarcoma 2.0)
  • Article
  • Open Access
31 Citations
6,499 Views
17 Pages

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

  • María del Mar Noblejas-López,
  • Lucía Gandullo-Sánchez,
  • Eva M. Galán-Moya,
  • Raquel López-Rosa and ,
  • David Tébar-García,
  • Cristina Nieto-Jiménez,
  • Mónica Gómez-Juárez,
  • Miguel Burgos,
  • Atanasio Pandiella and
  • Alberto Ocaña
  • + 5 authors+ 0 author

Cyclin-dependent kinases (CDKs) are a broad family of proteins involved in the cell cycle and transcriptional regulation. In this article, we explore the antitumoral activity of a novel proteolysis-targeting chimera (PROTAC) compound against CDK9. Br...

(This article belongs to the Special Issue Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0)
  • Article
  • Open Access
2 Citations
3,077 Views
18 Pages

A Structural Investigation of the Interaction between a GC-376-Based Peptidomimetic PROTAC and Its Precursor with the Viral Main Protease of Coxsackievirus B3

  • Alessia De Santis,
  • Deborah Grifagni,
  • Andrea Orsetti,
  • Elena Lenci and ,
  • Antonio Rosato,
  • Mariapina D’Onofrio,
  • Andrea Trabocchi,
  • Simone Ciofi-Baffoni,
  • Francesca Cantini and
  • Vito Calderone
  • + 5 authors+ 0 author

6 October 2024

The conservation of the main protease in viral genomes, combined with the absence of a homologous protease in humans, makes this enzyme family an ideal target for developing broad-spectrum antiviral drugs with minimized host toxicity. GC-376, a pepti...

(This article belongs to the Section Molecular Structure and Dynamics)
  • Article
  • Open Access
7 Citations
2,529 Views
19 Pages

N-Degron-Based PROTAC Targeting PLK1: A Potential Therapeutic Strategy for Cervical Cancer

  • Pethaiah Gunasekaran,
  • Sang Chul Shin,
  • Yeon Sil Hwang,
  • Jihyeon Lee and ,
  • Yeo Kyung La,
  • Min Su Yim,
  • Hak Nam Kim,
  • Tae Wan Kim,
  • Eunjung Yang and
  • Jeong Kyu Bang
  • + 10 authors+ 5 authors

Background: Cervical cancer remains a major global health concern, with existing chemotherapy facing limited effectiveness owing to resistance. Polo-like kinase 1 (PLK1) overexpression in cervical cancer cells is a promising target for developing nov...

(This article belongs to the Section Drug Targeting and Design)
  • Review
  • Open Access
2 Citations
1,821 Views
19 Pages

Breast cancer (BC) is a major global public health problem. Classical therapies have limited success on the treatment of BC; therefore, new therapeutic options are needed. Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that...

(This article belongs to the Special Issue Targeted Degradation of Proteins and Beyond)
  • Article
  • Open Access
5 Citations
5,370 Views
16 Pages

PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia

  • Alicia Perzolli,
  • Christian Steinebach,
  • Jan Krönke,
  • Michael Gütschow and ,
  • C. Michel Zwaan,
  • Farnaz Barneh and
  • Olaf Heidenreich
  • + 2 authors+ 0 author

10 January 2025

Background: Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin–proteasome system to selectively degrade target proteins. This innovative technology has shown remarkable efficacy and specif...

  • Article
  • Open Access
62 Citations
6,803 Views
19 Pages

Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity

  • Friedrich Hahn,
  • Stuart T. Hamilton,
  • Christina Wangen,
  • Markus Wild and ,
  • Jintawee Kicuntod,
  • Nadine Brückner,
  • Jasmine E. L. Follett,
  • Lars Herrmann,
  • Ahmed Kheimar and
  • Manfred Marschall
  • + 8 authors+ 3 authors

27 November 2021

Human cytomegalovirus (HCMV) is a major pathogenic herpesvirus that is prevalent worldwide and it is associated with a variety of clinical symptoms. Current antiviral therapy options do not fully satisfy the medical needs; thus, improved drug classes...

(This article belongs to the Section Macromolecules)
  • Review
  • Open Access
42 Citations
9,089 Views
16 Pages

Extensive progress in understanding the molecular mechanisms of cancer growth and proliferation has led to the remarkable development of drugs that target cancer-driving molecules. Most target molecules are proteins such as kinases and kinase-associa...

(This article belongs to the Special Issue Resistance to Targeted Therapies in Human Cancer)
  • Article
  • Open Access
10 Citations
4,839 Views
17 Pages

17 May 2025

In PROTAC molecules, the design of the linker directly affects the formation efficiency and stability of the target protein–PROTAC–E3 ligase ternary complex, making it a critical factor in determining degradation activity. However, curren...

(This article belongs to the Special Issue Development and Application of Computational Chemistry Methods)
  • Article
  • Open Access
1 Citations
875 Views
20 Pages

Myeloid cell leukemia-1 (MCL-1) is a cellular survival protein belonging to the Bcl-2 protein family and is overexpressed in human colorectal cancer (CRC). Background: This study aimed to reduce cancer progression by suppressing the MCL-1 protein usi...

(This article belongs to the Special Issue Gastrointestinal Cancers: From Pathogenesis to Treatment)
  • Article
  • Open Access
7 Citations
3,130 Views
22 Pages

Advanced PROTAC and Quantitative Proteomics Strategy Reveals Bax Inhibitor-1 as a Critical Target of Icaritin in Burkitt Lymphoma

  • Peixi Zhang,
  • Ziqing Zhang,
  • Jie Li,
  • Meng Xu and ,
  • Weiming Lu,
  • Ming Chen,
  • Jiaqi Shi,
  • Qiaolai Wang,
  • Hengyuan Zhang and
  • Jieqing Liu
  • + 9 authors+ 4 authors

2 December 2024

Understanding the molecular targets of natural products is crucial for elucidating their mechanisms of action, mitigating toxicity, and uncovering potential therapeutic pathways. Icaritin (ICT), a bioactive flavonoid, demonstrates significant anti-tu...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
1 Citations
1,237 Views
35 Pages

Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death

  • Mohamed Abdelsalam,
  • Melisa Halilovic,
  • Ramy Ashry,
  • Husam Nassar and ,
  • Frank Erdmann,
  • Matthias Schmidt,
  • Oliver H. Krämer and
  • Wolfgang Sippl
  • + 3 authors+ 0 author

Background/Objectives: Acute myeloid leukemia (AML) is a hematological malignancy frequently driven by mutations in the FLT3 gene, particularly internal tandem duplications (FLT3-ITD), which contribute to aberrant cell proliferation and resistance to...

(This article belongs to the Special Issue Advances in Enzyme Inhibitors and Protein Degraders as Anticancer Agents)
  • Article
  • Open Access
10 Citations
4,899 Views
26 Pages

Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design

  • Tommaso Palomba,
  • Giusy Tassone,
  • Carmine Vacca,
  • Matteo Bartalucci and ,
  • Aurora Valeri,
  • Cecilia Pozzi,
  • Simon Cross,
  • Lydia Siragusa and
  • Jenny Desantis
  • + 4 authors+ 0 author

17 November 2022

The field of targeted protein degradation, through the control of the ubiquitin–proteasome system (UPS), is progressing considerably; to exploit this new therapeutic modality, the proteolysis targeting chimera (PROTAC) technology was born. The...

(This article belongs to the Special Issue Trends and Applications in Computationally Driven Drug Repurposing)
  • Article
  • Open Access
5 Citations
2,586 Views
18 Pages

Effectiveness of PROTAC BET Degraders in Combating Cisplatin Resistance in Head and Neck Cancer Cells

  • Natalie Luffman,
  • Fereshteh Ahmadinejad,
  • Ryan M. Finnegan,
  • Marissa Raymond and ,
  • David A. Gewirtz and
  • Hisashi Harada
  • + 1 author+ 0 author

Head and neck squamous cell carcinoma (HNSCC) remains challenging to treat despite multimodal therapeutic approaches. Cisplatin treatment is effective and cost-efficient, although chemoresistance and disease recurrence limit its efficacy. Understandi...

(This article belongs to the Collection Feature Papers in “Molecular Biology”)
  • Review
  • Open Access
35 Citations
10,500 Views
27 Pages

PROTACs in the Management of Prostate Cancer

  • Poornachandra Yedla,
  • Ahmed O. Babalghith,
  • Vindhya Vasini Andra and
  • Riyaz Syed

25 April 2023

Cancer treatments with targeted therapy have gained immense interest due to their low levels of toxicity and high selectivity. Proteolysis-Targeting Chimeras (PROTACs) have drawn special attention in the development of cancer therapeutics owing to th...

(This article belongs to the Special Issue Past, Present and Future of Novel Therapeutic Modalities in Development for Targeted Protein Degradation)
  • Review
  • Open Access
75 Citations
14,275 Views
32 Pages

Recent Advances in PROTACs for Drug Targeted Protein Research

  • Tingting Yao,
  • Heng Xiao,
  • Hong Wang and
  • Xiaowei Xu

7 September 2022

Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically, PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and the specific ligand of E3 ubiquitin ligase, respectively, via a suitable li...

(This article belongs to the Special Issue Recent Advances of Novel Pharmaceutical Designs for Anti-cancer Therapies)
  • Article
  • Open Access
27 Citations
5,200 Views
15 Pages

Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs

  • Ponien Kou,
  • Elizabeth S. Levy,
  • An D. Nguyen,
  • Donglu Zhang and ,
  • Shu Chen,
  • Yusi Cui,
  • Xing Zhang,
  • Fabio Broccatelli,
  • Jennifer Pizzano and
  • Vijay Sethuraman
  • + 10 authors+ 5 authors

Proteolysis-Targeting Chimeras (PROTACs) are a promising new technology in drug development. They have rapidly evolved in recent years, with several of them in clinical trials. While most of these advances have been associated with monovalent protein...

(This article belongs to the Special Issue Advanced Liposomes for Drug Delivery)
  • Review
  • Open Access
65 Citations
9,905 Views
14 Pages

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

  • Rui Li,
  • Miao Liu,
  • Zhenya Yang,
  • Jiao Li and ,
  • Yuxin Gao and
  • Ruirong Tan
  • + 1 author+ 0 author

12 December 2022

The PROteolysis TArgeting Chimeras (PROTACs) is an innovative technique for the selective degradation of target proteins via the ubiquitin–proteasome system. Compared with traditional protein inhibitor drugs, PROTACs exhibit advantages in the e...

(This article belongs to the Special Issue Past, Present and Future of Novel Therapeutic Modalities in Development for Targeted Protein Degradation)
  • Article
  • Open Access
1,833 Views
17 Pages

Thalidomide-Based PROTACs: A Viable Strategy Against Trypanosomatids?

  • Romina Manarin,
  • Gianfranco Frattini,
  • Victoria L. Alonso,
  • Victoria Boselli and ,
  • Giselle R. Bedogni,
  • Elvio Rodríguez Araya,
  • Diego M. Moreno and
  • Esteban Serra
  • + 3 authors+ 0 author

Background: In recent years, compounds known as Proteolysis Targeted Chimeras (PROTACs) have revitalized the field of bioactive molecule design. These compounds promote proteolysis of therapeutic targets by recruiting them to ubiquitin ligases. One o...

(This article belongs to the Collection Anti-Parasite Drug Discovery)
  • Review
  • Open Access
31 Citations
10,449 Views
21 Pages

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities

  • Xuelian Liu,
  • Anjin Wang,
  • Yuying Shi,
  • Mengyuan Dai and ,
  • Miao Liu and
  • Hong-Bing Cai
  • + 1 author+ 0 author

26 January 2023

The epigenetic regulation of gene functions has been proven to be strongly associated with the development and progression of cancer. Reprogramming the cancer epigenome landscape is one of the most promising target therapies in both treatments and in...

(This article belongs to the Special Issue Past, Present and Future of Novel Therapeutic Modalities in Development for Targeted Protein Degradation)
  • Article
  • Open Access
  • Best Paper Award
34 Citations
8,421 Views
13 Pages

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

  • Sajid Khan,
  • Lin Cao,
  • Janet Wiegand,
  • Peiyi Zhang and ,
  • Maria Zajac-Kaye,
  • Frederic J. Kaye,
  • Guangrong Zheng and
  • Daohong Zhou
  • + 3 authors+ 0 author

17 March 2024

BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC). Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) induces dose-limiting thrombocytopenia through on-target BCL-xL inhibition in p...

(This article belongs to the Section Cell Microenvironment)
  • Review
  • Open Access
19 Citations
5,408 Views
26 Pages

Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications

  • Arvind Negi,
  • Kavindra Kumar Kesari and
  • Anne Sophie Voisin-Chiret

26 September 2022

Nonselective cell damage remains a significant limitation of radiation therapies in cancer. Decades of successful integration of radiation therapies with other medicinal chemistry strategies significantly improved therapeutic benefits in cancer. Adva...

(This article belongs to the Special Issue Synchrotron Radiation for Medical Applications)
  • Review
  • Open Access
716 Views
24 Pages

PROTACs in Oncology: Emerging Frontiers for Next-Generation Cancer Therapeutics

  • Salahuddin,
  • Renu Sharma,
  • Mohamed Jawed Ahsan,
  • Avijit Mazumder and ,
  • Kavita Rana,
  • Rajnish Kumar and
  • Chandana Majee
  • + 2 authors+ 0 author

15 September 2026

PROTACs represent a cutting-edge approach to the discovery of innovative cancer therapies. By exploiting the cell’s ubiquitin–proteasome system, PROTACs induce the selective degradation of target proteins, providing a distinct advantage o...

  • Review
  • Open Access
101 Citations
20,846 Views
29 Pages

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

  • Nuwayo Ishimwe Sincere,
  • Krishnan Anand,
  • Sumel Ashique,
  • Jing Yang and
  • Chongge You

A potential therapeutic strategy to treat conditions brought on by the aberrant production of a disease-causing protein is emerging for targeted protein breakdown using the PROTACs technology. Few medications now in use are tiny, component-based and...

(This article belongs to the Section Medicinal Chemistry)
  • Review
  • Open Access
8 Citations
5,964 Views
15 Pages

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives

  • Makenzie Vorderbruggen,
  • Carlos A. Velázquez-Martínez,
  • Amarnath Natarajan and
  • Adam R. Karpf

Ovarian cancer is the deadliest gynecologic malignancy. The majority of patients diagnosed with advanced ovarian cancer will relapse, at which point additional therapies can be administered but, for the most part, these are not curative. As such, a n...

(This article belongs to the Special Issue Ovarian Cancer: Advances on Pathophysiology and Therapies)
  • Review
  • Open Access
10 Citations
3,986 Views
20 Pages

PROTACs in Antivirals: Current Advancements and Future Perspectives

  • Jiacheng Jin,
  • Mengxiang Quan,
  • Xueyan Cao,
  • Yun Zhang and ,
  • Xiangwei Xu and
  • Zunyuan Wang
  • + 1 author+ 0 author

18 August 2025

Proteolysis-targeting chimera (PROTAC) technology has demonstrated remarkable progress in tumor therapy, attributed to its unique capability of catalytically degrading “undruggable” targets. In the context of the ongoing global health thr...

(This article belongs to the Section Medicinal Chemistry)
  • Article
  • Open Access
4 Citations
1,650 Views
17 Pages

Development and Evaluation of Liposomal Celastrol-PROTACs for Treating Triple-Negative Breast Cancer

  • Xuebin Li,
  • Chaoqun Yu,
  • Gongyi Zheng,
  • Yanghong Li and ,
  • Weiguo Cao and
  • Fan Wang
  • + 1 author+ 0 author

16 September 2025

Background: Based on our previous study, Celastrol-based proteolysis-targeting chimeras (Celastrol-PROTACs) were shown to induce apoptosis in 4T1 cells by selectively degrading GRP94 and CDK1/4 through the endogenous ubiquitin–proteasome system...

(This article belongs to the Section Pharmaceutical Technology)
  • Review
  • Open Access
61 Citations
12,326 Views
15 Pages

Recent Advances of Degradation Technologies Based on PROTAC Mechanism

  • Mingchao Xiao,
  • Jiaojiao Zhao,
  • Qiang Wang,
  • Jia Liu and
  • Leina Ma

7 September 2022

PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in recent years. Here, we introduce the history of PROTAC, and summarize the recent advances in novel typ...

  • Review
  • Open Access
49 Citations
9,029 Views
24 Pages

Proteolysis-targeting chimeras (PROTACs) are rapidly emerging as a potential therapeutic strategy for cancer therapy by inducing the degradation of tumor-overexpressing oncogenic proteins. They can specifically catalyze the degradation of target onco...

(This article belongs to the Special Issue Nanomedicine to Enhance Innate and Adaptive Anticancer Immunity)
  • Review
  • Open Access
18 Citations
7,862 Views
43 Pages

Targeting selective estrogen subtype receptors through typical medicinal chemistry approaches is based on occupancy-driven pharmacology. In occupancy-driven pharmacology, molecules are developed in order to inhibit the protein of interest (POI), and...

(This article belongs to the Section Drug Targeting and Design)
  • Review
  • Open Access
37 Citations
13,285 Views
23 Pages

The classical low-molecular-weight drugs are designed to bind with high affinity to the biological targets endowed with receptor or enzymatic activity, and inhibit their function. However, there are many non-receptor or non-enzymatic disease proteins...

(This article belongs to the Special Issue Advances in Anticancer Agent)
  • Article
  • Open Access
2 Citations
1,303 Views
33 Pages

Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs)

  • Abdallah M. Alfayomy,
  • Sven Hagemann,
  • Matthias Schmidt,
  • Ali Fouad and ,
  • Mohamed Ayman El-Zahabi,
  • Stefan Hüttelmaier and
  • Wolfgang Sippl
  • + 2 authors+ 0 author

17 March 2026

The oncogenic transcription factor MYC is a key driver of the development and progression of various types of cancer, but its intrinsically disordered structure and dependence on protein–protein interactions make it a difficult therapeutic targ...

(This article belongs to the Special Issue Organic Molecules in Drug Discovery and Development)

of 7